Artiva was featured in San Diego Business Journal following its $300 million financing to support the continued advancement of AlloNK® in autoimmune disease. The article discusses the company’s planned Phase 3 trial in refractory rheumatoid arthritis and its focus on developing an outpatient-ready, scalable approach to deep B-cell depletion. Read the article here (subscription may…
